Biomerica Q1 Loss Widens to $1.2M; Going-Concern Doubt Reiterated Despite $2.7M Cash
BMRA sits 29% above its 52-week low of $1.45 on light trading volume (0.2× avg).
Summary
Biomerica's fiscal Q1 FY2027 net loss widened to $1,232,000 as gross margin collapsed to 8.1%, and management reiterated substantial doubt about continuing as a going concern despite $2,733,000 of cash. Early Medicare reimbursement for inFoods IBS is ramping, but the company remains dependent on external financing.
Key Events · Earnings and Guidance · BMRA
-
Q1 Loss Widens to $1.2M
Net loss of $1,232,000 for the quarter ended August 31, 2026, versus net income of $2,000 a year earlier, on revenue of $1,265,000 (down 8%).
-
Gross Margin Collapses to 8.1%
Gross profit fell to $103,000 from $424,000 as cost of sales rose 22% to $1,162,000, driven by contract manufacturing mix, higher OTC product costs, and lower clinical lab volume.
-
Going-Concern Doubt Reiterated
Management states existing cash and cash equivalents are insufficient to fund operations for the next twelve months; accumulated deficit stands at $58,175,000.
-
Cash Rises on August Placement
Cash and cash equivalents increased to $2,733,000 from $1,308,000 at May 31, 2026, reflecting $2,231,000 gross proceeds from the August 26, 2026 private placement of 1,393,705 shares at $1.60 per share.
Analysis · BMRA · Life Sciences
The fiscal Q1 FY2027 results show the core business deteriorating: revenue fell 8% to $1,265,000 and gross margin collapsed to 8.1% from 30.7% a year ago, producing a $1,232,000 net loss versus roughly break-even a year earlier. Management again states substantial doubt about the company's ability to continue as a going concern, with $2,733,000 of cash and $2,572,000 of working capital insufficient to fund the next twelve months. The August 26, 2026 private placement ($2,231,000 gross at $1.60 per share) lifted cash from $1,308,000, but operating cash burn widened to $802,000 in the quarter, so the runway remains short. Early Medicare reimbursement traction for inFoods IBS is the one bright spot: 22 Medicare-related orders in September versus 10 in August, with 32 locations set up to order as of October 15, 2026. With a $250 million shelf now effective and a director not standing for re-election at the December 11 annual meeting, the company is signaling it will need to keep raising capital.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 36.7% of the 962 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMRA was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $1.45 to $3.21. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.